Latest From Biotech Now

Inter Partes Review – a Useful Tool for Overcoming Freedom-to-Operate Obstacles

Basic CMYK

By Eric K. Steffe, Eldora L. Ellison, Ph.D., Todd Spalding, and Deborah A. Sterling, Ph.D. For companies facing freedom-to-operate obstacles, the AIA provides a number of tools for dealing with troublesome patents.  While proceeding at risk in the face of such patents sometimes make sense, inter partes review (IPR) provides a viable option for challenging them and should be considered as a valuable addition to one’s freedom-to-operate toolbox. Inter partes reexamination (IPX), which (bio)pharma used Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Are Politics Killing the U.S. Animal Biotech Industry?

salmon

A number of national newspapers ran an in-depth Associated Press article this week on the continuing saga of the AquAdvantage salmon and the challenge of its developer, Massachusetts-based AquaBounty Technologies, to stay afloat. The fish, genetically engineered to reach market weight in half the time of a conventional salmon, is a sustainable answer to the world’s demand for high-quality seafood protein, but its application for approval with the U.S. Food and Drug Administration (FDA) remains Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Housing Inventory Going Fast

Chicago

With roughly 80,000 bioscience jobs in more than 3,500 businesses across all bioscience sectors, it is no wonder the 2013 BIO International Convention is returning to Chicago, April 22- 25, 2013. With a large presence in all biotech sectors – agricultural feedstock and chemicals, drugs and pharma, medical devices and equipment, research, testing and medical laboratories and bioscience-related distribution, attendees will have the opportunity to meet with and visit premier R&D facilities, from national laboratories Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

Data Exclusivity Protects Innovators and Assures Investors

medical_research_thumb

Biotechnology companies must have some certainty that they can protect their investment in the development of new breakthrough therapies for a substantial period of time. This protection helps companies secure much-needed venture capital funding, which is the lifeblood of the industry. A failure to include substantial data exclusivity would undermine incentives to invest in biomedical innovation and thus would slow progress in the development of breakthrough therapies to improve the health and lives of patients Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Tips for Building Your Brand at the 2013 BIO International Convention

exhibit-floor

Anxious to get a head start on your Convention planning but don’t know where to begin? Join the BIO Convention team’s monthly webinar series. Open to all attendees, pavilion organizers, delegations and prospective attendees, the webinar gives direct access to the drivers of the event, BIO staff. Last week’s webinar, Branding at BIO, focused on what to expect for exhibitor booth partnering, cost and time saving tips when dealing with Chicago union labor and how to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,